



# INVESTOR FORUM

October 17-18, 2018

Westin St. Francis, San Francisco, CA

***Accelerate discovery.  
Amplify returns.***



Biotechnology  
Innovation  
Organization

The BIO Investor Forum is an international biotech investor conference focused on investment trends and opportunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2019.

**1,000+ attendees**

**2,760+ partnering meetings scheduled**





**170 private and public company presentations**

**369 partnering companies**

## ***Why Investors Attend***

-  **HEAR** from and meet with executives at the top life sciences growth companies.
-  **EVALUATE** fresh investment opportunities including compatible, complementary and competitive companies.
-  **BENEFIT** from candid panel discussions with leading clinical experts and investigators with insights on pipeline research and clinical practice.
-  **GET A ‘BIG PICTURE’ OVERVIEW** of the industry and the issues affecting product innovation, capitalization, and commercialization.

## ***Why Companies Attend***

-  **MEET** one-on-one with new and current investors, analysts, and partnering companies.
-  **GET THE PULSE** on the latest life sciences investment trends from sophisticated investment and company executives.
-  **PRESENT** your business case to qualified investors and potential partners.
-  **NETWORK** with peers, investors and collaboration partners.

# 2018 Advisory Committee



**Mahima Agochiya, PhD**

Business Development & Program Manager,  
SPARK Translational Research Program,  
Stanford University



**Katherine Andersen**

Senior Market Manager, Head of East Coast &  
Central, Life Science & Healthcare, Silicon Valley  
Bank (SVB)



**Vinay Bhaskar, PhD**

Principal, MPM Capital



**Janice Bourque**

Managing Director, Life Sciences,  
Hercules Technology Growth Capital



**Jason Camm**

Chief Medical Officer, Thiel Capital LLC



**John Chambers**

President and Head of Investment  
Banking, H.C. Wainwright & Co.



**Alice Chen, PhD**

Vice President, Accelerator Life Science  
Partners



**Jung Choi**

Chief Business & Strategy Officer, Global  
Blood Therapeutics



**Shelley Chu, MD, PhD**

Partner, Abingworth



**Douglas Crawford, PhD**

Partner, BioInnovation Capital



**Rajeev Dadoo, PhD**

Partner, S.R. One Limited



**Jie D'Elia, PhD**

Executive Director, Business Develop-  
ment Transactions, Bristol-Myers Squibb



**Gini Deshpande, PhD**

Founder & Chief Executive Officer,  
NuMedii



**Tao Huang, PhD, JD**

Venture Partner, Cenova Capital

# 2018 Advisory Committee



**Charlotte Hubbert, PhD,**  
Partner, Gates Foundation Venture  
Capital



**Margaret Kim**  
Executive Director, Life Sciences,  
JPMorgan Chase & Co.



**Ravi Kiron, PhD**  
Head, BioPharma External Innovation, EMD  
Serono



**Jennifer Landress, CMP**  
Senior Vice President and Chief  
Operating Officer, Biocom



**Sabrina Martucci Johnson**  
President and Chief Executive Officer,  
Daré Bioscience



**Carolyn Ng, PhD**  
Principal, Vertex Ventures HC



**Sara Radcliffe**  
President & CEO, California Life Sciences  
Association (CLSA)



**Stephen Ritoch**  
Chairman & Chief Executive Officer,  
Blaise Group International



**Mahendra G. Shah, PhD**  
Managing Director, Vivo Capital



**Komathi Stem**  
Founder & Chief Executive Officer,  
monARC Bionetworks



**Alex de Winter, PhD**  
Managing Director, GE Ventures



**Samuel Wu, MD, PhD**  
Managing Director, Acuris Partners



**Asish Xavier, PhD**  
Vice President, Venture Investments,  
Johnson & Johnson Innovation – JJDC, Inc.



**Matthew Yates, PhD**  
Vice President, Corporate Business  
Development, Eli Lilly and Company



# BIO SPARK Showcase Event

**Tuesday, October 16, 2018**

| Time              | Spark Affiliate and Program   |
|-------------------|---|
| 1:00 PM - 1:10 PM | Welcome from SPARK Translational Research Program, Stanford Medicine<br>Kevin Grimes, MD, Co-Director   |
| 1:10 PM - 1:30 PM | Stanford University<br>New Small Molecule Anesthetics for high risk infants/ elderly<br>Ed Bertaccini   |
| 1:30 PM - 1:50 PM | SPARK Colorado- Aurora Oncology<br>Intravesical DAB389EGF for the treatment of bladder cancer<br>Professor Michael Glode  |
| 1:50 PM - 2:10 PM | Stanford University<br>Novel Treatment for Kidney Cancer<br>Arvin Gouw/ Dean Felsher  |
| 2:10 PM - 2:30 PM | SPARK Colorado- ThromboTherapeutics Inc<br>tPA-Challenged™ Viscoelastometric Hemostatic Assay for Early Identification of Life-Threatening Coagulopathy in Trauma<br>Michael Chapman, Resident at Department of Radiology |
| 2:30 PM - 2:40 PM | Break   |
| 2:40 PM - 3:00 PM | Stanford University<br>Transient Telomere extension for liver failure<br>John Ramunas   |
| 3:00 PM - 3:20 PM | SPARK Finland- SCellOmics<br>Novel single cell omics methods<br>Saavalainen, Päivi  |
| 3:20 PM - 3:40 PM | Stanford University- Hyalos Therapeutics<br>Stopping Autoimmune Disease by Oral Induction of Treg<br>Marc Unger   |
| 3:40 PM - 4:00 PM | SPARK Finland- Sartar Therapeutics<br>Targeted GIST therapy<br>Harri Sihto  |
| 4:00 PM - 4:10 PM | Break   |
| 4:10 PM - 4:30 PM | Stanford University<br>Platform technology for gene delivery<br>Ole Audun Werner Haabeth  |
| 4:30 PM - 4:50 PM | SPARK Taiwan<br>Development of the drug to treat opioid addiction<br>Amy Lai  |
| 4:50 PM - 5:10 PM | SPARK Australia- Monash University<br>Curative approach to inflammatory and autoimmune diseases<br>Laurence Meagher   |
| 5:10 PM - 5:30 PM | Stanford University- Facile Therapeutics<br>Development of a de-risked, phase 2-ready treatment for C. difficile infections<br>Marc Navre   |
| 5:30 PM - 6:30 PM | Reception   |

## SPARK AT STANFORD

The BIO SPARK Showcase Event provides an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding. The symposium will feature a dozen presentations from a mix of international, translational research start-ups.

This pre-#BIF18 Showcase is free to attend but RSVP is required at <https://www.bio.org/events/bio-investor-forum/spark-showcase>

# #BIF18 Programming Schedule

## Plenary Luncheon Fireside Chats

**Rowan Chapman, PhD,**  
**Head of Johnson & Johnson Innovation, California**

Thursday, October 18, 2018

12:00 pm - 1:25 pm



**Ed Hurwitz, JD, MBA,**  
**Managing Director, MPM Capital**

Wednesday, October 17, 2018

12:00 PM - 1:25 PM

Moderator: Susanne Mulligan, Managing Director,  
Life Sciences Banking, BMO Capital Markets



## Panels

### **Navigating Checkpoint Inhibitors' Clinical Results: Lessons for CEOs and Investors**

Wednesday, October 17, 8:30-9:40 am

In the past three years, the number of U.S. clinical trials testing checkpoint inhibitors in combination immunotherapies has quintupled to nearly 1,300 trials. Two types of combination trials are attracting particular attention to their performance magnifying checkpoint inhibitors: IDO inhibitors and oncolytic viruses. The former combination has delivered initial disappointments in the past year, while combining oncolytic viruses with checkpoint inhibitors has seen promising clinical results. This panel reviews the current landscape of checkpoint inhibitor development, highlighting lessons that can be gained from recent achievements and setbacks in combination immunotherapies.

#### **Panelists:**

- Karin Jooss, PhD, Executive Vice President of Research and Chief Scientific Officer, Gritstone Oncology
- Eugene P. Kennedy, MD, Chief Medical Officer, NewLink Genetics
- Angèle Maki, PhD, Executive Director, MRL BD&L, Merck & Co., Inc.

# #BIF18 Programming Schedule

## **Learning from Translational Research Successes to Attract Investment**

*Wednesday, October 17, 9:45-10:40 am*

As biomedical entrepreneurs seek to apply the newest biomedical research results to invest new treatment options that might help patients, a “valley of death” in funding availability continues to endure between the academic researcher and therapies ready to begin clinical trials. Over the past decade, publicly-financed organizations designed to bridge this “valley” with development grants have created a track record with notable success stories. Such non-dilutive funding sources reduce risks during the proof-of-concept stage and make investments more attractive to equity investors. Panelists in this session will explore the characteristics of academic spinouts that continued past the grant stage to attract major and repeated investments from venture capital as well as that demonstrated therapeutic progress.

**Moderator: Simone Fishburn, PhD, Editor, *BioCentury* and *BioCentury Innovations***

### **Panelists:**

- Alice Chen, PhD, Vice President, Accelerator Life Science Partners
- Kevin Grimes, MD, Co-Director, SPARK Translational Research Program, Stanford University
- Paul Laikind, PhD, President and Chief Executive Officer, ViaCyte
- Stephanie Marrus, Director, Entrepreneurship Center, University of California, San Francisco (UCSF)
- Shyam Patel, PhD, Associate Director for Portfolio Development and Review California Institute for Regenerative Medicine (CIRM)

## **Using Microbiome-Based Therapies to Improve Patient Outcomes**

*Wednesday, October 17, 10:45-11:40 am*

Investments in microbiome-related companies have accelerated across the past three years, demonstrating high investor expectations for results. As the first pioneering companies have pushed research into clinical development and started publishing results, those findings and new avenues beyond the gut and digestion-related therapies suggest diagnostic and treatment opportunities in inflammation, neurology, and dermatology, among others. This panel will discuss a range of microbiome-based approaches for innovations to improve patient outcomes. Topics include microbiome transplants, bioengineered probiotics, next-generation antibiotics, and microbiome-based drug discovery platforms.

### **Panelists:**

- David Berry, MD, PhD, General Partner, Flagship Pioneering
- Karim Dabbagh, PhD, Chief Scientific Officer, Second Genome
- Paul Miller, MD, Chief Scientific Officer, Synlogic
- Glyn Edwards, Chief Executive Officer, Summit Therapeutics
- Lihi Segal, Co-Founder and Chief Executive Officer, Day Two
- Wenyan Shi, PhD, Chief Executive Officer and Chief Scientific Officer, Forsyth Institute
- Emma Taylor, MD, Chief Executive Officer, Naked Biome



# #BIF18 Programming Schedule

## ***Reaching Chinese Investors: Considerations for an IPO in Hong Kong***

*Wednesday, October 17, 2:00-2:55 pm*

The Hong Kong Stock Exchange is capturing worldwide attention as it modifies listing rules to permit biotech companies, opening the door for Chinese firms seeking public market financing as well international firms eyeing the support of investors in China. In just the exchange's first few weeks more than USD 1 billion in new offerings have generated funding that will be applied to accelerate clinical research on behalf of patients. This session will examine cross-border perspectives on the appetite of China-based investors for biotechs and the criteria to determine the attractiveness of listing on the exchange for foreign entities as Hong Kong sets its sights at becoming a major biotech funding source.

**Moderator: Joshua Berlin, Executive Director & Editor of New Ventures, BioCentury**

### **Panelists:**

- Katherine Andersen, Head of Healthcare Corporate Finance and East/Central Life Science, Silicon Valley Bank
- Keting Chu, MD, PhD, Venture Partner, LYFE Capital
- Jie D'Elia, PhD, Executive Director, Business Development Transactions, Bristol-Myers Squibb
- Michael Keyoung, MD, PhD, Managing Director, C-Bridge Capital

## ***CFIUS and You: Understanding the Newly Expanded Regulatory Reviews of Cross-Border Investments***

*Wednesday, October 17, 3:15-4:10 pm*

In August 2018, President Trump signed into law new rules regarding foreign direct investment in U.S. companies that any cross-border equity investor, dealmaker, or CEO seeking funding should incorporate into their planning. The Committee on Foreign Investment in the United States (CFIUS), which has mostly focused on national security reviews of acquisitions in military technology industries, now will devote additional resources to scrutinize venture capital and minority-investment deals where companies possess sensitive, personal data of U.S. citizens. Some previously voluntary deal notification filings will become mandatory, with penalties for noncompliance. This panel will examine the impact that these new investment rules will have on the biotechnology sector. Expert speakers will describe the government review process and provide guidance on when incorporating a potential CFIUS review into deal negotiations makes sense.

**Moderator: Lisa Schaefer, Director, Tax & Financial Services Policy, Biotechnology Innovation Organization**

### **Panelists:**

- Thilo Hanemann, Director, Rhodium Group
- Louis Lehot, Partner, Co-Chair, US Emerging Growth and Venture Capital, Co-Managing Partner, Silicon Valley office, DLA Piper
- Mark E. Plotkin, Partner, Covington & Burling LLP



# #BIF18 Programming Schedule

## *View from the Board: Responding to an Acquisition Offer*

*Wednesday, October 17, 4:15-5:10 pm*

More than 60 biopharmaceutical acquisitions of private companies took place over the past four years. One of the greatest challenges faced by a leadership team is responding to an acquisition offer. The inability to predict when such an offer is likely to be received and the deadline pressure to react quickly heighten the importance of preparing for such scenarios in advance within a board of directors. Also, the inherent tension of boards including both venture investors and managers/founders may force difficult conversations regarding valuation and risk. This panel will review how to structure those conversations and decisions to be as productive as possible.

**Moderator: Michael J. O'Donnell, Partner, Morrison & Foerster, LLP**

### **Panelists:**

- Corey Goodman, Managing Partner, venBio Partners
- Linda Graiss, MD, former Chief Executive Officer, Ocera Therapeutics
- Nina Kjellson, General Partner, Canaan Partners
- Camille Samuels, Partner, Venrock

## *Expanding the Toolbox of Neurodegeneration Therapies*

*Thursday, October 18, 8:30-9:40 am*

Results of a Phase II clinical trial presented at the July 2018 Alzheimer's Association International Conference suggest that an anti-beta amyloid antibody shows promise in slowing cognitive decline in Alzheimer's patients, creating hope, but also refueling the debate regarding assumptions about the biology of neurodegeneration. In a field historically focused on beta-amyloid plaques as primary targets but challenged to demonstrate new approvals, what are alternative hypotheses to neurodegenerative treatment development? This panel brings together investors, scientists, and companies expanding the toolbox of neurodegeneration therapies. Collectively, panelists will not only discuss the relevance of misfolded proteins, but also broaden the conversation to include the role of neuro-inflammation, alternative mechanisms of action, and other therapeutic targets for treating neurodegeneration.

### **Speakers:**

- Steven Braithwaite, PhD, Chief Scientific Officer, Alkahest
- Carole Ho, MD, Chief Medical Officer, Denali Therapeutics
- Robert Paul, MD, PhD, Chief Medical Officer, Alektor
- Charles S. Ryan, PhD, Chief Executive Officer, Neurotrope
- Julie Anne Smith, President and CEO, E-Scape Bio Inc.



# #BIF18 Programming Schedule

## ***Accelerating Biotech R&D through Cloud Computing***

*Thursday, October 18, 9:45-10:40 am*

The development of cloud computing allows start-ups to scale their IT costs at the same pace as their ability to create value from them, tapping into analytics resources that traditionally were only available after massive up-front investment. For biotechs in particular, the variable data intensity of different stages of the drug development process makes cloud computing a major enhancement for R&D productivity. As real-world data and genomic sequencing become more widespread inputs to clinical trials, the data needs of biopharmas will increase exponentially, as will the challenge of integrating these data sources and the opportunity to make progress addressing unmet patient needs at a pace closer to the IT industry's speed. This panel will feature therapeutic and IT experts describing processes and applications that are making a difference today.

**Moderator:** Elliot Meschnik, MD, PhD, Healthcare and Life Science Ventures, Amazon Web Services, Amazon

### **Speakers:**

- Matt Brauer, PhD, Data Science Consultant, Third Rock Ventures
- Karina Chmielewski, Senior Director, Platform Operations, Third Rock Ventures
- Daphne Koller, PhD, Founder and Chief Executive Officer, insitro
- Craig Muir, Partner/ Chief Technology Officer, Third Rock Ventures
- Charles Wolfus, Vice President, Digital Health and Business Operations, MyoKardia

## ***"Digiceuticals" as a New Class of FDA-Approved Therapeutics: Investment & Partnering Opportunities***

*Thursday, October 18, 10:45-11:40 am*

Within the past year, the FDA has launched a provider pre-certification program as a pilot to manage the expansion of "digiceuticals" or digital therapeutics that produce clinical benefits for patients via interaction with a software application or mobile app. This innovative regulatory approach seeks to provide discipline around clinical utility with the iterative improvements enabled by software versus standard manufactured medicines. Given the near-instant worldwide distribution platforms of mobile apps, the technology enables fundamental changes in managing interactions with patients to understand and treat disease, with clear collaboration benefits between biopharma and digital therapy providers. This session will feature companies trying to expand this frontier, the investors distinguishing among the competing technologies, the therapeutic partners who might benefit from such apps, and experts on the most likely pathways innovations will take to reach patients.

### **Speakers:**

- Jeffrey Abraham, Vice President of Market Access & Trade, Akili Interactive
- Antoun Nabhan, Vice President of Corporate Development, Pear Therapeutics
- David Klein, Executive Chairman, President, and Chief Executive Officer, Click Therapeutics

# #BIF18 Programming Schedule

## ***How Real-World Evidence Can Improve Clinical Trial Productivity***

*Thursday, October 18, 1:45-2:40 pm*

As a greater percentage of health care records are digitized, plus with the emergence of patient-provided data sets via wearables and other devices, therapy developers have much greater ability to distill insights from existing data rather than solely relying upon “started from scratch” clinical trials to learn about a disease. Companies are combining new analytical techniques with careful human screening of real world data sources such as electronic health records, insurance billing records, and patients’ mobile devices to develop real-world evidence regarding which patient populations might respond best to a new treatment under development and which diagnostic markers might streamline clinical trial recruitment. In the light of the FDA’s new guidance on real-world evidence this panel will explain how traditional approaches to clinical trial design may be enhanced to save time and money, while improving productivity and outcomes for patients.

### **Panelists:**

- Ken Carson, MD, PhD, Senior Medical Director, Flatiron Health
- Christine Lemke, Co-founder & President, Evidation Health
- Gracie Lieberman, Director of Regulatory Policy, Genentech
- Jeremy Rassen, ScD, Co-Founder, President and Chief Science Officer, Aetion, Inc.
- Komathi Stem, Founder & Chief Executive Officer, monARC Bionetworks

## ***Applying Artificial Intelligence to Improve Therapy Development Today***

*Thursday, October 18, 3:00-3:55 pm*

As new techniques in artificial intelligence expand the functionality of software to find useful results from large data sets, progress companies are already folding such tools into their developments of new therapies to address unmet needs of patients. For example, companies are using the “always-on” power of computers to filter existing molecular libraries and model new drug discovery techniques in ways never before possible. This session will feature experts working at the intersection of information technology, therapy delivery, and new drug development, who can show the exponential power of machine learning and other artificial intelligence approaches to turn data into medicine.

**Moderator: Gini Deshpande, PhD, Founder & Chief Executive Officer, NuMedii**

### **Panelists:**

- Josep Bassaganya-Riera, DVM, PhD, Chairman and Chief Executive Officer, Landos Biopharma
- Jeffrey Brewer, President and Chief Executive Officer, Bigfoot Biomedical
- Edward Painter, Co-Founder and Chief Executive Officer, A2A Pharma



# #BIF18 Programming Schedule

## ***Market Outlook – IPOs Ascendant and Watching M&A Valuations***

Thursday, October 18, 4:00-4:55 pm

Despite heightened political discussion of the value of marketed medicines, the biopharma investor community continues to increase its support. As the industry has gained traction on new drug approvals through 2018, the financial dollars have followed with record public and private offerings. The attractive IPO market has however resulted in fewer M&A deals than prior years, with high pre-money IPO valuations for later-stage companies making it less enticing for them to accept early-exit offers. This has led to an M&A shift to focus on early-stage companies. The session will examine the current deals and market trends while highlighting the path forward.

***“BIO One-on-One Partnering is the best mechanism for meeting potential investors and collaborators.”***



***“Great mix of different investors and well executed format.”***



***“Panel sessions are interesting and informative.”***





# Participating Investors

Below is the preliminary list of participating investors for the 2018 BIO Investor Forum.

|   |   |   |
|---|---|---|
| AbbVie  | First Republic Bank                       | Paulson Investment Company                        |
| AbbVie Ventures                                   | Five Corners Capital                      | Pharmstandard Ventures                            |
| ABES Venture Partners                             | FMG Ventures                              | Pivotal bioVenture Partners                       |
| Abingworth Management                             | Fortress Biotech                          | PoC Capital                                       |
| Agent Capital                                     | Frazier Healthcare Partners               | Premier Partners                                  |
| Agilent Technologies                              | Fusion Fund                               | Presidio Partners                                 |
| Altamont Pharmaceutical Holdings                  | GE Ventures                               | Prevail Partners                                  |
| aMoon Fund  | Genesys Capital Partners                  | Qiming US Healthcare Ventures                     |
| AngelMD   | Genoa Ventures                            | Quantum Capital Management                        |
| ARCH Venture Partners                             | GPB Capital                               | Quark Venture                                     |
| Asajes Ventures                                   | Grey Sky Venture Partners                 | RBV Capital                                       |
| Aspire Capital Partners                           | HealthCare Royalty Partners               | Red Tailed Hawk Venture Partners                  |
| Asset Management Ventures                         | Helicase Venture                          | Relentless Pursuit Partners                       |
| Astellas Innovation Management                    | Hemi Ventures                             | Remiges Ventures                                  |
| Astellas Venture Management                       | Horizon Technology Finance                | Roche   |
| ATEL Ventures                                     | Illumina Accelerator                      | Roche Venture Fund                                |
| ATEM Capital                                      | Illumina Ventures                         | RTP Capital                                       |
| AuGC BioFund LP                                   | Innovation Endeavors                      | Salubris Pharma                                   |
| Bay City Capital                                  | Innovation Network Corporation of Japan   | Samsara BioCapital                                |
| Berkeley Catalyst Fund                            | IPF Partners                              | Santen Pharmaceutical Co.                         |
| BGI Venture                                       | JAFECO Co.                                | Satter Medical Technology Partnership             |
| Bill and Melinda Gates Foundation Venture Capital | JDRF T1D Fund                             | SBA   |
| BioPacific Investors                              | Johnson & Johnson Innovation Center       | Silicon Valley Bank                               |
| Bios Partners                                     | Joyance Partners                          | Sofinnova Ventures                                |
| BioSense Global                                   | Life Science Angels                       | Solar Capital                                     |
| Biotech Alliances International                   | Lilly Asia Ventures                       | SR One  |
| BOSON Capital Partners                            | Lincoln Park Capital                      | Surveyor Capital                                  |
| Brace Pharma Capital                              | Locust Walk                               | Syzygy Therapeutics                               |
| Brain Trust                                       | Lyfe Capital                              | Taiho Ventures                                    |
| Brandon Capital Partners                          | Matthews Asia                             | Taiwania Capital                                  |
| Bridge Bank                                       | Matthews International Capital Management | Terra Magnum Capital Partnership                  |
| BridgeBio   | Maxpro Ventures                           | The Brain Trust Accelerator Fund                  |
| Canaan Partners                                   | MBL Venture Capital Co.                   | The Engine  |
| Canadian Imperial Bank of Commerce                | Medpro Investors                          | The Leukemia & Lymphoma Society                   |
| Capital IP  | Medstart Ventures                         | Thiel Capital                                     |
| Cato BioVentures                                  | Merieux Developpement                     | Tosoh USA   |
| C-Bridge Capital                                  | Militia Hill Ventures                     | TransPacific Venture Capital Partners             |
| CDRD Ventures                                     | Mission Bay Capital                       | Trinitas Capital                                  |
| CH Innovations                                    | Mitsui & Co. Global Investment            | UCSF  |
| CID4  | Moore Venture Partners                    | University of Stirling                            |
| Codon Capital                                     | MP Healthcare Venture Management          | US Angels   |
| Columbia Threadneedle Investments                 | MPM Capital                               | venBio Partners                                   |
| Crosswave Management                              | MyBioGate                                 | Venrock Healthcare Capital Partners               |
| CRV   | Nan Fung Life Sciences                    | Ventac Partners                                   |
| CSC Leasing                                       | NanoDimension                             | Versant Ventures                                  |
| Data Collective Venture Capital                   | NEA                                       | Viking Global Investors                           |
| DEFTA Partners                                    | New Leaf Venture Partners                 | Vivo Capital                                      |
| Dolby Family Ventures                             | Novo Ventures                             | W Global Capital/International Capital Management |
| Dorset Capital                                    | Oceaniq Capital Partners                  | WBB Securities                                    |
| Dorset Capital and Par Equity USA                 | OCV                                       | Westlake Ventures                                 |
| Dynamk Capital                                    | OmniCyte                                  | WestPark Capital                                  |
| East West Bank                                    | Opus Point Partners                       | WI Harper Group                                   |
| EDB Investments                                   | Oresund Capital                           | Xeraya Capital Life Venture                       |
| Efung Capital                                     | Osage University Partners                 | XOMA  |
| Emerson Collective                                | OSF Healthcare Ventures                   | Yonjin Capital                                    |
| ESC Advisors                                      | Otsuka Pharmaceutical                     | YStrategies                                       |
| Esperante   | Oxford Finance                            |   |
| EWB   | Palo Alto Investors                       |   |
| Excelyrate Capital                                | Panacea Venture Healthcare                |   |
| Finance Technology Leverage                       | Pangaea Ventures                          |   |
|   | Pathway BioVentures                       |   |

# Presenting Companies

The following is the list of presenting companies for the 17th Annual BIO Investor Forum. Presenters will consist of Discovery Companies (under \$25M raised to date in Seed or Series A financing rounds), established private companies (over \$25M raised and in Series B and above) and emerging public companies. A special track of NIH SBIR grant recipients will be presenting also.

Download a spreadsheet of data from the presenting companies for sorting, editing, and notes at <https://bit.ly/BIF18presenters>

## CARDIOVASCULAR

Antidote Therapeutics, Inc.  
Artgen Inc  
Berlin Cures Holding AG  
BioCardia  
Elsius Biomedical Corporation  
Medicure Inc.  
New Horizons Pharma  
RECARDIO Inc.  
Resverlogix Corp.  
ZeClinics SL

## CNS/NEUROLOGICAL

AcuraStem Incorporated  
Alkahest, Inc.  
Amygdala Neurosciences, Inc.  
APRINOIA Therapeutics Inc.  
Aural Analytics, Inc.  
Axsome Therapeutics, Inc.  
BioXcel Therapeutics  
Conzl OU  
Cytex Ltd  
DEHA  
Embera NeuroTherapeutics, Inc.  
EncepHeal Therapeutics  
E-Scape Bio  
Genervon Biopharmaceuticals, LLC  
Lauren Sciences LLC  
NeuroDiagnostics LLC  
NeuroRx, Inc.  
Neurotez Inc.  
VistaGen Therapeutics, Inc.  
Zosano Pharma Corporation  
Zynerba Pharmaceuticals

## DERMATOLOGY

Aegle Therapeutics Corp.  
Azitra, Inc.  
DelNova, Inc.  
Histogen, Inc.

## DIAGNOSTICS

Deton  
Diacarta Inc  
Fry Laboratories, LLC  
Fusion Genomics Corporation  
GenomeMe Lab Inc.  
ImCare Biotech  
Interpace Diagnostics Group, Inc.  
KIYATEC  
Navidea Bio  
OncoCyte Corporation  
POC Medical Systems Inc.  
VERAVAS, Inc.  
YouGene

## DIGITAL HEALTH

20/20 GeneSystems, Inc.  
Beyond Verbal Communication Ltd.  
BitMED  
Cerebra Health Inc.  
Click Therapeutics, Inc.  
Health 2.0 Cairo chapter

## GASTROINTESTINAL

AzurRx BioPharma, Inc.  
Landos Biopharma  
Leading BioSciences, Inc.

## GENE/CELL THERAPY

Advancells  
American Gene Technologies  
BioTime  
Caladrius Biosciences, Inc.  
Caribou Biosciences  
Chameleon Biosciences  
Dendreon Pharmaceuticals LLC  
Fibrocell Science, Inc.  
HPBio Inc.  
Incyus Therapeutics, Inc.  
MaxCyte, Inc.  
Monarch Biosciences, Inc.  
Regrow Biosciences Pvt Ltd  
ViaCyte, Inc.

## IMMUNOLOGY

ActoBio Therapeutics  
Ativo TX (dba IL-2Rx Inc.)  
Heat Biologics  
Orion BioScience

## INFECTIOUS DISEASES

Chameleon Biosciences  
Codagenix, Inc.  
Cyclenium Pharma  
CytoDyn Inc.  
Genekam Biotechnology AG  
Invirsa, Inc.  
Lakewood-Amedex, Inc.  
NOBIO LTD.  
SaNOtize Research and Development Corp  
Squarex, LLC  
Verndari Inc.

## INFLAMMATION

Acquist Therapeutics, Inc.  
Immunic AG  
Innovate Biopharmaceuticals, Inc.  
RHNanopharmaceuticals, LLC  
SFA Therapeutics, LLC

## MEDICAL DEVICES

Aethlon Medical, Inc.  
Aktivax, Inc  
Biomere Tech  
CytoSorbents Corporation  
gel-e, Inc.  
GFD Pharmaceuticals  
ivWatch, LLC  
Kestrel Labs, Inc.  
Microdermics Inc.

## METABOLIC DISEASES

AmideBio LLC  
Antag Therapeutics ApS  
Caliway Biopharmaceuticals Co., Ltd.  
CohBar, Inc.  
Gila Therapeutics, Inc.  
Poxel SA

## MULTIPLE THERAPEUTICS

7 Hills Pharma  
AbTLAS  
Axolo Pharma  
Dr. Reddy's Laboratories  
Eli Lilly and Company  
Merck & Co., Inc.

Orum Therapeutics Inc  
PIN Pharma, Inc.  
RubrYc Therapeutics, Inc.  
Sandoz Inc  
Selenity Therapeutics, Inc.  
VIVUS, Inc.  
XOMA Corporation

## NON-PROFIT/PATIENT ADVOCACY GROUP

STEM to Market

## ONCOLOGY

Ab Studio Inc.  
Apexian Pharmaceuticals  
BendaRx Corp  
BeyondSpring Pharmaceuticals  
BioVaxys LLC  
Bristol-Myers Squibb  
Cairn Biosciences  
Checkpoint Therapeutics, Inc.  
ChemioCare  
Circle Pharma, Inc.  
Cyclacel Pharmaceuticals, Inc.  
Cytosin Therapeutics  
CytRx Corporation  
Diffusion Pharmaceuticals Inc.  
Digenomix Corporation  
DotBio Pte. Ltd.  
EnduRx Pharmaceuticals Inc.  
Fusion Pharmaceuticals Inc.  
Genisphere LLC  
Genprex, Inc.  
GLAdiator Biosciences, Inc.  
Greenwich LifeSciences, Inc.  
Handa Pharmaceuticals, Inc.  
Heidelberg Pharma AG  
Hillstream BioPharma Inc.  
IGF Oncology, LLC  
Immix Biopharma, Inc  
Immunomic Therapeutics, Inc.  
IMV Inc.  
Infinity Pharmaceuticals, Inc.  
Ingenovax LLC  
IsoRay Inc.  
Lantern Pharma Inc  
Lexi Pharma Inc.  
Natsar Pharmaceuticals  
Notable Labs  
Nurix, Inc.  
Onconova Therapeutics, Inc.  
OncoSenX, Inc  
OncoTAB, Inc.  
PanTher Therapeutics, Inc.  
Photolitec, LLC  
RadioMedix Inc  
Rafael Pharmaceuticals  
Rain Therapeutics  
Reglagene Holding, Inc.  
Salarius Pharmaceuticals  
Saturn Biosciences  
Sermonix Pharmaceuticals LLC  
SignalRx Pharmaceuticals, Inc.  
Socium Therapeutics, Inc.  
Susavion Biosciences, Inc.  
Tradewind BioScience, Inc.  
Xyphos Biosciences, Inc.

Zenith Epigenetics Ltd

## OPHTHALMOLOGY

Kedalion Therapeutics, Inc.  
MyopiaCure  
Nemus Bioscience, Inc.  
OcuMedic, Inc.  
Serentrix

## ORPHAN/RARE DISEASES

ArTara Therapeutics, Inc.  
Imara Inc.,  
InMed Pharmaceuticals Inc.  
Innova Therapeutics  
Mezzion Pharma  
Sartar Therapeutics  
Sinfonia Biotherapeutics, Inc.  
Valley Fever Solutions

## OTHER

BBN Cardio Therapeutics  
BlackThorn Therapeutics  
Nucleus Network  
PhenoMx  
RxMP Therapeutic, Inc.  
Xylome

## PAIN MANAGEMENT

Phoenix PharmaLabs, Inc.  
Sindolor LLC  
Theracaine, LLC

## PLATFORM FOR THERAPEUTICS

Aro Biotherapeutics  
Arpeggio Biosciences, Inc.  
Bioasis Technologies Inc.  
Flaskworks LLC  
Matinas BioPharma Holdings, Inc.  
Second Genome, Inc.

## REGENERATIVE MEDICINE

Miromatrix Medical Inc.  
Orig3n, Inc.  
Sernova Corp.  
X-Therma Inc.

## REPRODUCTIVE/SEXUAL HEALTH

Daré Bioscience, Inc.  
Urigen Pharmaceuticals, Inc.

## RESPIRATORY

Enlil Therapeutics  
Novoclem Therapeutics

## TOOLS/DRUG DEVELOPMENT SUPPORT TECH

Biovista, Inc.  
FenoLogica Biosciences, Inc.  
iGenomX-International Genomics Corporation  
Insight RX, Inc.  
Soplix  
Universal Sequencing Technology  
Xcell Biosciences  
X-Therma Inc.

# Registration

BIO offers a number of ways for conference attendees to save money on their registration fees. Discounted rates apply to the following:

- ✓ Biotech companies that have raised less than \$25 million in capital.
- ✓ Presenting companies bringing three or more attendees.
- ✓ Companies bringing more than two employees.
- ✓ Corporations or other entities that use biotechnology or related technologies for research and development of products or information.
- ✓ Academic institutions.

**Qualified institutional and venture investors are eligible for complimentary registration.**

**Register today at [bio.org/investorforum](http://bio.org/investorforum)**

## Hotel/Venue Information

**Westin St. Francis Hotel**  
**335 Powell Street**  
**San Francisco, California 94102**

***Book your room today*** to also receive the discounted room rate.  
Reservation requests are based on availability, space is limited.

# 2018 Sponsors

## BIO Double Helix Sponsors

abbvie



Bristol-Myers Squibb

Johnson & Johnson



MERCK

INVENTING FOR LIFE

## BIO Helix Sponsor

Lilly

## Supporting Bank Sponsors

BMO



HCW

H.C. WAINWRIGHT & CO.

## Conference Sponsors



AMERICAN LABORATORY TRADING

AON

Empower Results®

BLAISE GROUP INTERNATIONAL

Executive & Board Search

CHUBB

CVS

Intelligent Development

MORRISON  
FOERSTER



Rho

ShareVault

Share documents. Simply, securely.



THE MONEY CHANNEL



TORREYA

vwr

part of avantor

## Co-Hosts

CLSA

California Life Sciences Association

BIOCOM



SoCalBio  
Southern California  
Biomedical Council

Contact us today for a tailored sponsorship package that will meet your business objectives. Please contact:

Liz Colangelo at [lcolangelo@bio.org](mailto:lcolangelo@bio.org) or (202) 962-6656.

For more information on BIO sponsorships, please contact [sponsor@bio.org](mailto:sponsor@bio.org).

## Join the conversation:

Learn more about Biotechnology at [bio.org](http://bio.org)

Engage with the Biotech Community at [BIOTECH-NOW.org](http://BIOTECH-NOW.org)

Follow us on Twitter [@bio1x1](https://twitter.com/bio1x1) and tweet with [#BIF18](https://twitter.com/BIF18)

Become a fan on Facebook ([facebook.com/IAmBiotech](https://facebook.com/IAmBiotech))